Phase 2 N=25 Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
Acute Myelogenous Leukemia
Primary: Progression Free Survival — 21 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=110 Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA
Anterior Cruciate Ligament Reconstruction
Primary: POST-OPERATIVE HEMARTHROSIS — 26.7; 37.3 ml
N/A N=9 Neurosciences-Intensive Care Unit Electrical Stimulation
Intensive Care (ICU) Myopathy
Primary: Duration of Intubation — 10.22 days
Phase 2 N=25 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Renal Cancer
Primary: Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group
Phase 1 N=18 Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects
Healthy Adult Male
Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 — 47.4; 44.9; 46.1 ng/mL
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 2 N=24 Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 16.7; 8.3 Percentage of Participants
Phase 1 N=78 A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Safety and Tolerability
Primary: Number of Participants With of Adverse Events (AEs) — 3; 1; 1; 1 Count of Participants
N/A N=60 The Effect of Motivational Interviewing and Education Based on Watson's Theory of Human Caring in Hemodialysis
Renal Disease · Adherence, Treatment · Quality of Life
Primary: Change From Baseline in Adherence to Fluid Intake on the Fluid Control in Hemodialysis Patients Scale at Week 12 — 1.37; -0.17; 3.31; 0.50 units on a scale — p=<0.001
N/A N=6 Effects of a Compliant Arm Support on Post-stroke Upper Extremity Range of Motion
Arm Weakness as a Consequence of Stroke
Primary: Percent Change From Baseline in Reachable Workspace — 27; -71 percent change
Phase 3 N=444 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 8.57; 6.34 months — p=0.0051
Phase 2 N=289 Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Lymphoma
Primary: Complete Remission (CR) Rate — 0.62; 0.75 proportion of participants — p=0.02
Phase 2 N=27 Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Combined Therapy - Median Progression Free Survival — 36 months
N/A N=204 Impact of Opioid Free Anesthesia on Outcome After DIEPflap Surgery
Major and Minor Surgical Complications
Primary: Number of Patients With One or More Complications — 10; 85 Participants — p=<0.001
Phase 4 N=180 Computerized Cognitive Training for Diabetic Elderly Veterans
Diabetes Mellitus, Type 2
Primary: Diabetes Self-management — 14.9; 15.1 score on a scale